BioSpace News Archive

Parkinson & Movement Disorder Alliance (PMD Alliance, www.pmdalliance.org) and Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, t

Studies presented at two leading breast imaging conferences demonstrate ProFound AI helps radiologists identify normal mammograms and those with increased likelihood of malignancy with precision

Neurona Therapeutics , a biotherapeutics company advancing neural cell therapies for the treatment of neurological disorders, today announced the presentation of preclinical data from its lead inhibitory neuron cell therapy program, which is being developed for the treatment of drug-resistant focal epilepsy.

Galectin Therapeutics also announces new $10 million convertible debt financing from its Chairman, Richard E. Uihlein

Neurelis, Inc., announced today that it is presenting five posters at the American Academy of Neurology (AAN) Annual Meeting being held virtually from April 17 through April 22.

Citrine Medicine, a China-based rare disease therapeutics company, and Sinopharm Group, a Chinese pharmaceutical company, today announced a strategic partnership to accelerate the commercialization of rare disease drugs in China.

Stand Up To Cancer® and Mirati Therapeutics Inc. – a late-stage targeted oncology company – announced that Mirati will contribute a $4 million grant to SU2C to develop new approaches to treat patients with KRAS mutant cancers, as a part of the SU2C Catalyst® program.

INVO Bioscience, Inc. (NASDAQ: INVO), a medical device company focused on commercializing the world’s only in vivo Intravaginal Culture System (IVC), INVOcell®, an effective and affordable treatment for patients diagnosed with infertility, today announced the execution of a partnership agreement with Lyfe Medical, LLC

CVS Pharmacy, the retail division of CVS Health, announced the availability of three over-the-counter COVID-19 testing options in stores and online.

LivaNova PLC (NASDAQ:LIVN), today announced it has randomized the 300th patient in the Autonomic Regulation Therapy to Enhance Myocardial Function and Reduce Progression of Heart Failure With Reduced Ejection Fraction (ANTHEM-HFrEF) Pivotal Study,